Bispecific antibodies offer numerous potential clinical benefits, and the number of bispecifics in development continues to soar. However, production of these molecules can present challenges such as heavy-light chain mispairing - affecting yields of the correct species, downstream processing workloads, COGs and timelines.
In this animation
We cover how bYlok® technology works, how it can drive correct heavy-light chain pairing to >95%, and how you can access it via a license agreement to enable you to overcome industry-wide challenges in bispecific production.
See also
For more information, see our bYlok® Bispecific Pairing Technology Brochure.